Moxetumomab Pasudotox: First Global Approval
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-1000-9
Abstract: Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an… read more here.
Keywords: pasudotox; approval; cell leukaemia; moxetumomab pasudotox ... See more keywords
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood-2017-02-749101
Abstract: Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL). Moxetumomab pasudotox is a recombinant anti-CD22 immunotoxin. A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative… read more here.
Keywords: phase; moxetumomab pasudotox; lymphoblastic leukemia; acute lymphoblastic ... See more keywords